Opinion of the Technical Scientific Commission of AIFA on the administration of a booster dose of the Spikevax vaccine against COVID-19
The Technical Scientific Commission of AIFA (CTS), meeting on 28 October 2021, expressed its opinion on the administration of a booster dose of the vaccine against COVID-19 Spikevax (Moderna). Taking note of the EMA's decision, the CTS establishes to make the booster dose of the Spikevax vaccine available, at least six months after the second dose, in subjects aged 18 years or older. The Commission also reiterates that, as already established for Pfizer's booster dose, this opportunity should be offered as a priority to subjects already indicated for the Comirnaty (Pfizer) vaccine.
The booster dose of the Spikevax vaccine will also be included in the list referred to in Law 648/96 to allow its heterologous use.